INNOVIVA, INC. Deferred Income Tax Assets, Net
INNOVIVA, INC. (INVA) had Deferred Income Tax Assets, Net of $0 as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DeferredIncomeTaxAssetsNet · last filed 2026-02-25
- 2025-12-31: Deferred Income Tax Assets, Net $0.00.
- 2025-09-30: Deferred Income Tax Assets, Net $7.98M.
- 2025-06-30: Deferred Income Tax Assets, Net $12.93M.
- 2025-03-31: Deferred Income Tax Assets, Net $12.29M.
| Period end | Deferred Income Tax Assets, Net |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-25 |
| 2025-09-30 | $7.98M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $12.93M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $12.29M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $12.05M 10-K · filed 2026-02-25 |
| 2024-09-30 | $14.88M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $11.45M 10-Q · filed 2024-07-31 |
| 2023-12-31 | $0.00 10-K · filed 2025-02-26 |
| 2023-09-30 | $4.95M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $6.33M 10-Q · filed 2023-08-02 |
| 2022-12-31 | $0.00 10-Q · filed 2023-11-01 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-09 |
| 2022-06-30 | $23.27M 10-Q · filed 2022-07-27 |
| 2022-03-31 | $22.40M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $17.33M 10-K · filed 2023-02-28 |
| 2021-09-30 | $28.16M 10-Q · filed 2021-10-27 |
| 2021-06-30 | $48.69M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $74.02M 10-Q · filed 2021-04-28 |
| 2020-12-31 | $93.76M 10-K/A · filed 2022-03-17 |
| 2020-09-30 | $109.49M 10-Q · filed 2020-10-28 |
| 2020-06-30 | $118.35M 10-Q · filed 2020-07-29 |
| 2020-03-31 | $138.24M 10-Q · filed 2020-04-29 |
| 2019-12-31 | $154.17M 10-K · filed 2021-02-25 |
| 2019-09-30 | $166.56M 10-Q · filed 2019-10-30 |
| 2019-06-30 | $177.11M 10-Q · filed 2019-07-24 |
| 2019-03-31 | $187.55M 10-Q · filed 2019-05-01 |
| 2018-12-31 | $196.05M 10-K · filed 2020-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |